The aromatase inhibitor anastrozole inhibits estrogen synthesis. Fulvestrant binds and accelerates degradation of estrogen receptors. We hypothesized that these two agents in combination might be more ...

To investigate whether suppression of plasma estradiol and estrone sulfate levels by the aromatase inhibitors (AIs) anastrozole and letrozole is related to body mass index (BMI) in postmenopausal ...

A study by researchers from Queen Mary University of London shows that bone loss known to be associated with the use of the breast cancer prevention drug Anastrozole partially reverses, particularly ...

Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: ...

The Queen Mary University of London professor leading an international breast cancer study says anastrozole—rather than tamoxifen—should be the preventive drug-of-choice for post-menopausal women at ...

Share on Pinterest Anastrozole can reduce breast cancer risk after menopause, but does it come with its own risks? Image credit: shironosov/Getty Images. A drug used as a breast cancer treatment has ...

Among women with hormone-receptor–positive breast cancer, the odds of recurrence or death are reduced by 47 and 26 percent, respectively, after five years of treatment with tamoxifen. The drug has ...

Compared with anastrozole alone, the combination of fulvestrant and anastrozole significantly improved time without disease progression and extended the median overall survival of women with endocrine ...

Study author Jack Cuzick, MD, Queen Mary University, London, United Kingdom, explained that another endocrine therapy, tamoxifen, has previously been demonstrated to have a similar extended effect in ...

Review the side-effects of Anastrozole as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Anastrozole is an orally active, non-steroidal aromatase inhibitor which appears effective as neoadjuvant treatment of breast cancer. Histological changes have been evaluated in biopsies from large, ...

London: Anastrozole, a daily pill to prevent breast cancer, will now be available to thousands of more women in the UK after being cleared for wider use. The drug has been used to treat hormone-driven ...